Rising Cancer Cases, Technological Advancements, and Expanding CAR-T Applications Continue to Drive Global Market Growth
Delray Beach, FL, May 27, 2026 (GLOBE NEWSWIRE) — The global CAR T-cell therapy market is projected to grow from USD 6.78 billion in 2026 to USD 13.56 billion by 2031, registering a CAGR of 14.9% during the forecast period. Rapid technological advancements, increasing investment from pharmaceutical and biotechnology companies, and expanding clinical adoption are accelerating growth across the global CAR-T landscape.
CAR T-cell therapies are increasingly being adopted for relapsed and refractory hematologic cancers, supported by ongoing label expansions and earlier-line treatment adoption. Improvements in manufacturing technologies, safety management, and real-world treatment outcomes are also strengthening confidence among healthcare providers and treatment centers worldwide.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=47772841
What Is Driving Growth in the CAR T-Cell Therapy Market?
Technological advancements in CAR-T development and manufacturing are playing a major role in market expansion. Automated and semi-automated manufacturing systems are improving product consistency, reducing contamination risks, and enabling more scalable production processes.
At the same time, growing investments in oncology research, cell therapy infrastructure, and next-generation CAR engineering are accelerating innovation. Companies are increasingly developing dual-target, armored, and allogeneic CAR-T therapies to improve efficacy and expand treatment applications beyond traditional blood cancers.
Why Is the Industry Focusing on Solid Tumor Applications?
While hematologic cancers remain the primary commercial focus, companies are increasingly targeting solid tumors and non-oncology indications as the next major growth opportunity. Researchers are exploring advanced CAR engineering approaches to overcome the biological barriers associated with solid tumors and improve treatment response rates.
The expansion into larger patient populations could significantly increase market potential over the next decade. In addition, ongoing innovation in immune profiling, biomarker discovery, and translational analytics is helping improve patient stratification and therapy personalization.
What Challenges Continue to Impact Market Expansion?
Despite strong growth potential, high treatment costs and reimbursement challenges continue to limit broader market adoption. CAR-T therapies involve complex and individualized manufacturing processes that can exceed USD 350,000 per treatment, creating financial barriers for healthcare systems and patients.
The market also faces long-term safety monitoring challenges due to evolving regulatory requirements surrounding secondary malignancies and adverse events. Ongoing safety surveillance and post-treatment monitoring requirements are increasing operational complexity for hospitals and treatment centers.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=47772841
Which Segments Lead the CAR T-Cell Therapy Market?
By product, Carvykti held a leading market share in 2025 due to strong adoption in multiple myeloma treatment and positive real-world clinical performance. Its durable response rates and increasing use in earlier treatment lines have expanded the eligible patient population.
By target, CD19 remained the dominant segment due to its extensive clinical validation across B-cell malignancies and continued uptake across major treatment centers. Established treatment pathways and ongoing label expansions continue to strengthen CD19’s leadership position in the CAR-T market.
Why Do Hospitals Dominate CAR-T Therapy Adoption?
Hospitals accounted for the largest end-user share in 2025 because CAR-T administration requires highly specialized infrastructure, multidisciplinary oncology teams, and intensive patient monitoring capabilities.
Accredited hospital-based oncology and transplant centers remain critical for managing treatment logistics, inpatient infusion procedures, cytokine release syndrome (CRS), and neurotoxicity monitoring. These requirements continue to anchor CAR-T therapy delivery within advanced hospital settings globally.
Why Is Asia Pacific Emerging as a High-Growth Region?
Asia Pacific is becoming one of the fastest-growing regions in the CAR T-cell therapy market due to rising clinical trial activity, increasing investment in cell therapy infrastructure, and supportive regulatory pathways. Countries such as China, Japan, South Korea, and India are rapidly expanding domestic CAR-T development and manufacturing capabilities.
The region is also witnessing growing adoption of automated cell processing platforms, viral vector manufacturing technologies, and specialized CDMO services. Academic institutions and hospitals across Asia Pacific are increasingly collaborating with biotech firms to strengthen regional commercialization and treatment access.
Who Are the Leading Companies in the CAR T-Cell Therapy Market?
Major companies operating in the market include Bristol-Myers Squibb Company, Johnson & Johnson, Gilead Sciences, Inc., Novartis AG, JW Therapeutics, and ImmunoACT.
These companies are investing heavily in next-generation CAR-T technologies, manufacturing expansion, strategic collaborations, and product commercialization. Leading therapies such as CARVYKTI, ABECMA, BREYANZI, Kymriah, Yescarta, and Tecartus continue to strengthen the competitive landscape and drive market adoption globally.
Why Does the CAR T-Cell Therapy Market Matter Now?
The growing global cancer burden and increasing demand for personalized oncology treatments are positioning CAR-T therapies as a major advancement in cancer care. Continued innovation in gene engineering, manufacturing automation, and immune profiling is expected to improve treatment accessibility and long-term outcomes.
As pharmaceutical companies expand indications and invest in scalable manufacturing infrastructure, CAR T-cell therapy is expected to play a critical role in the future of precision medicine and advanced cancer treatment worldwide.
For more information, Inquire Now!
Discover Connected Healthcare Market Opportunities:
Drug Discovery Services Market
Drug Discovery Technologies Market
Injectable Drug Delivery Market
Immunotherapy Drugs Market
Pharmaceutical Drug Delivery Market
Get access to the latest updates on Top Companies in CAR T-Cell Therapy and CAR T-Cell Therapy Market Size
CONTACT: About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook . Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: [email protected] Visit Our Website: https://www.marketsandmarkets.com/
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.